Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.7325
+0.0074 (1.02%)
Nov 6, 2026, 4:00 PM EST - Market closed
Azitra Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
13
Market Cap
4.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 7.50K | -678.50K | -98.91% |
| Dec 31, 2023 | 686.00K | 402.00K | 141.55% |
| Dec 31, 2022 | 284.00K | 174.00K | 158.18% |
| Dec 31, 2021 | 110.00K | -315.00K | -74.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xenetic Biosciences | 3.26M |
| Evogene | 1.66M |
| AIM ImmunoTech | 95.00K |
| Cardio Diagnostics Holdings | 14.45K |
| Alaunos Therapeutics | 3.00K |
| Creative Medical Technology Holdings | 3.00K |
AZTR News
- 10 days ago - Azitra expands eligibility for Phase 1/2 clinical trial of ATR-04 - TheFly
- 10 days ago - Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors - PRNewsWire
- 13 days ago - Azitra’s ATR-COSF shows skin revitalizing effectivity in ex vivo study - TheFly
- 13 days ago - Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin - PRNewsWire
- 23 days ago - Azitra announces 1-for-10 reverse stock split - TheFly
- 23 days ago - Azitra, Inc. Announces Reverse Stock Split - PRNewsWire
- 5 weeks ago - Azitra completes Cohort 1 in Phase 1/2 clinical trial evaluating ATR04-484 - TheFly
- 5 weeks ago - Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance - PRNewsWire